CIDRAP newsletters options
The rheumatoid arthritis drug baricitinib was shown to reduce mortality in hospitalized COVID-19 patients, according to a randomized, controlled trial published in The Lancet Respiratory Medicine yesterday. Baricitinib acts as a Janus kinases inhibitor and is under emergency use authorization to treat severe COVID-19 by the US Food and Drug Administration.
Also, global health experts call on world leaders to hold a UN summit on ending the pandemic.
Even those who had mild COVID-19 are at increased risk for major declines in kidney function.
August was the fourth-worst month of the pandemic for new COVID-19 cases.
Admission screening for carbapenem-resistant Enterobacterales (CRE) at a Vietnamese children's hospital was associated with reduced CRE acquisition, hospital-acquired infections (HAIs), duration of hospital stay, and costs, according to a study published this week in Antimicrobial Resistance and Infection Control.
Pre-hospital antiplatelet therapy, most commonly aspirin, was associated with significantly lower in-hospital mortality rates for COVID-19 patients, according to a study this week in the Journal of Thrombosis and Haemostasis.
Wealthy nations have shipped less than 10% of the requested 1 billion doses by September.
Residents of states that lifted eviction bans were at an 83% higher risk for COVID-19 after 12 weeks.
Parents are split on whether mask mandates belong in schools, and colleges grapple with vaccine mandates.
After two doses of an mRNA-based COVID-19 vaccine, nearly 90% of immunocompromised patients had an antibody response, but it was about as third as strong as those with healthy immune systems, according to data published in the Annals of Internal Medicine yesterday.
Severity and the type of symptoms experienced appear to be the biggest factors in accepting a delayed antibiotic prescription for a respiratory tract infection (RTI), according to a UK survey published yesterday in PLOS Medicine.
CDC advisers vote unanimously to recommend the Pfizer-BioNTech vaccine for people ages 16 and up.
In addition, a research team based in South Africa described a new variant of interest called C.1.2.
The Delta variant was also tied to a higher rate of emergency care than the Alpha variant.
A new report from the World Economic Forum predicts a future of rising risks and costs from waterborne antimicrobial resistance (AMR).
High-risk adults with mild to moderate COVID-19 who receive a dose of casirivimab and imdevimab have lower hospitalization rates than those who don't, according to a randomized, controlled trial today in The Lancet's EClinicalMedicine. The casirivimab and imdevimab combination is under emergency use authorization by the US Food and Drug Administration.
Also, the CDC does not intend to revisit its pre-Delta COVID-19 guidelines for schools at this point.
After recall of the Pfizer drug, Apotex and Par Pharmaceutical are tapped to increase supply.
Officials are hopeful Africa can reach 10% of its population with vaccine by the end of September.
A third still have shortness of breath 1 year after hospital release.
